The closer we get to April 15th the more likely I think our chances of getting BARDA money. I would think that if BARDA was not satisfied with the FDA's path to drug approval as of this late date they would have said so by now. They have had the proposal and FDA feedback for at least 4 months now. Remember it has been almost a year since BARDA rejected the white paper back in early April 2012, and since then Biolabs has had numerous meetings with both BARDA and the FDA together . The BARDA people, in my opinion, would be in essence acting maliciously toward Biolabs development if they reject to fund research going forward at this late date. Practically speaking, they have #$%$ Biolabs development for about a year and strung them along waiting for funding and delayed them from finding outside money to continue their research so much sooner. Sure, the governments money is the best route to finance the company, but the time lost at this late date would probably be a wash. Of coarse we would of had to raise outside money and surely diluted shares many times over but the data that would have been generated by now at this time would surely have generated a partner and exposure that would have the stock price and company value much higher.
So either BARDA is sinister (has other objectives) and is malicious or I think we are very close to moving forward with what I think are final studies proving we have at least one of the remedies for ARS.
Google "bioshield program rocky start" for a Q&A with Health and Human Services Assistant Secretary for Preparedness and Response Nicole Lurie,
Here is the last question and answer...
GSN: What are some countermeasures that you hope or are planning to see focused on should Bioshield go ahead with that $2.8 billion?
Lurie: We still have a lot of work to do in the area of rad/nuke, we still have a lot of work to do in the area of thermal burns. Think about the fact that getting good products for both of those … we’ll probably revolutionize burn care in this country as we do it.
We have a lot of work to do in the chem area and we still have more work to do for some biothreats and for improving some of the products that we now have for biothreats so that they have a longer shelf life, so that they’re easier to use, that they don’t need [to be constantly kept in cold storage], those things.
As we solve those problems we solve many other problems for global vaccine programs as well.
So still a lot of work to do but I think we’re on a terrific trajectory now with so many promising products in the pipeline.